Evidence map›Paper›PMID 28648835›Full record

Observational studyDiabetes & metabolism2017

Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.

Y Nakatani, M Maeda, M Matsumura, R Shimizu, N Banba, Y Aso, T Yasu, H Harasawa

3 registry-linked trialsOpen access · hybridAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Diabetes & metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 69 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 4 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04046822 phase4unknown statusstarted 2019, after this paper: background citation

Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial

Ran2019Enrolled70Registered outcomes21Posted comparisons0ConditionsMicrobiome, Obesity, Weight LossArmsLiraglutide 6 MG/ML [Saxenda], Placebo
PMID 15505215PMID 15831718PMID 26912499PMID 27048547other papers from this trial
Open the trial in the graph
NCT06003985 completednot on this mapstarted 2023, after this paper: background citation

Assessment of Preoperative Gastric Content With Ultrasound in Patients Taking GLP1 Agonists

TypeobservationalSponsorHospital for Special Surgery, New YorkRan2023 to 2025Enrolled354ConditionsGastric Ultrasound, Glucagon-like Peptide 1, Point of Care UltrasoundArmsGastric Ultrasound Exam
NCT07756359 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy of the Dual GIP - GLP-1 Receptor Agonist Tirzepatide in Patients With an Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2026 to 2027Enrolled20ConditionsPouch, Ileal, Pouches, Ileoanal, Bowel Diseases, InflammatoryArmsTirzepatide, Loperamide, Diphenoxylate/Atropine
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Trial
  7. Article
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Y NakataniDepartment of Diabetes and Endocrinology, Dokkyo Medical University Nikko Medical Center, 632, Takatoku Nikkoshi, 321-2593 Tochigi, Japan. Electronic address: yu-naka@dokkyomed.ac.jp.
M MaedaDepartment of Gastroenterology, Dokkyo Medical University Nikko Medical Center, 632, Takatoku Nikkoshi, 321-2593 Tochigi, Japan.
M MatsumuraDepartment of Endocrinology and Metabolism, Dokkyo Medical University, 880, Kitakobayashi Shimotsugagun Mibumachi, 321-0293 Tochigi, Japan.
R ShimizuDepartment of Cardiovascular Medicine, Dokkyo Medical University Nikko Medical Center, 632, Takatoku Nikkoshi, 321-2593 Tochigi, Japan.
N BanbaDepartment of Diabetes and Endocrinology, Dokkyo Medical University Nikko Medical Center, 632, Takatoku Nikkoshi, 321-2593 Tochigi, Japan.
Y AsoDepartment of Endocrinology and Metabolism, Dokkyo Medical University, 880, Kitakobayashi Shimotsugagun Mibumachi, 321-0293 Tochigi, Japan.
T YasuDepartment of Cardiovascular Medicine, Dokkyo Medical University Nikko Medical Center, 632, Takatoku Nikkoshi, 321-2593 Tochigi, Japan.
H HarasawaDepartment of Pulmonary Medicine, Dokkyo Medical University Nikko Medical Center, 632, Takatoku Nikkoshi, 321-2593 Tochigi, Japan.
Dokkyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study evaluated the effects of a glucagon-like peptide-1 receptor agonist on gastrointestinal (GI) tract motility and residue rates by examining GI transit time and lumen using capsule endoscopy. MATERIAL AND

methodsGI motility and lumen were assessed by capsule endoscopy before and after liraglutide administration in 14 patients with type 2 diabetes mellitus (T2DM).

resultsGastric transit time in the group with diabetic neuropathy (DN) was 1:12:36±1:04:30h before liraglutide administration and 0:48:40±0:32:52h after administration (nonsignificant difference, P=0.19). Gastric transit time in the non-DN group was 1:01:30±0:52:59h before administration and 2:33:29±1:37:24h after administration (significant increase, P=0.03). Duodenal and small intestine transit time in the DN group was 4:10:34±0:25:54h before and 6:38:42±3:52:42h after administration (not significant, P=0.09) and, in the non-DN group, 3:51:03±0:53:47h before and 6:45:31±2:41:36h after administration (significant increase, P=0.03). The GI residue rate in the DN group was 32.1±24% before administration and 90.0±9.1% after administration (significant increase, P<0.001), and increased in all patients; in the non-DN group, it was 32.1±35.3% before and 78.3±23.9% after administration (significant increase, P<0.001), and also increased in all patients.

conclusionLiraglutide causes delayed gastric emptying and inhibits duodenal and small intestine motility. However, these GI movement-inhibiting effects may be decreased or absent in patients with DN-associated dysautonomia.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsAgedCapsule EndoscopyDiabetic NeuropathiesGastrointestinal MotilityGastrointestinal TransitGlucagon-Like Peptide-1 ReceptorHumansLiraglutideMaleMiddle AgedPhenylethyl Alcohol4-methyl-1-phenylpentan-2-olGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsLiraglutidePhenylethyl AlcoholDiabetic neuropathyGlucagon-like peptide-1Motility in gastrointestinal tractType 2 diabetes mellitus

Identifiers

PMID28648835
OpenAlexW2629223022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.